menu
    • menu
    [{"orgOrder":0,"company":"Accord BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Accord BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Accord BioPharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Accord BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Accord BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Accord BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Accord BioPharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Accord BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Accord BioPharma","sponsor":"Eversana","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Partnership","leadProduct":"Leuprolide Mesylate","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Accord BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Accord BioPharma \/ Eversana","highestDevelopmentStatusID":"15","companyTruncated":"Accord BioPharma \/ Eversana"},{"orgOrder":0,"company":"Accord BioPharma","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Accord BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Accord BioPharma \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Accord BioPharma \/ Intas Pharmaceuticals"},{"orgOrder":0,"company":"Accord BioPharma","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2025","type":"Acquisition","leadProduct":"Pegfilgrastim","moa":"G-CSF receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Accord BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Accord BioPharma \/ Accord BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Accord BioPharma \/ Accord BioPharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Accord BioPharma

    Menu

    Accord BioPharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Accord BioPharma

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Accord BioPharma

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pegfilgrastim

                            Therapeutic Area : Hematology

                            Study Phase : Approved FDF

                            Recipient : Coherus Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Accord BioPharma Announces Completion of UDENYCA Franchise Acquisition from Coherus

                            Details : Udenyca, a biosimilar to Neulasta (pegfilgrastim), expands the company's portfolio of FDA-approved products and accelerates Accord BioPharma's growth in the biosimilar industry.

                            Product Name : Udenyca

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            April 14, 2025

                            Lead Product(s) : Pegfilgrastim

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved FDF

                            Recipient : Coherus Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Accord BioPharma

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Accord BioPharma

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trastuzumab

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Accord BioPharma Gains FDA Approval of HERCESSI™ Biosimilar For Cancer

                            Details : Hercessi (trastuzumab-biosimilar) is biosimilar to Herceptin, which is indicatedfor the treatment of HER2 overexpressing breast cancer & metastatic gastric or gastroesophageal junction adenocarcinoma.

                            Product Name : Hercessi

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            September 18, 2024

                            Lead Product(s) : Trastuzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Accord BioPharma

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Accord BioPharma

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ustekinumab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Intas Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Accepts BLA for Dong-A ST's DMB-3115, a Proposed Biosimilar to Stelara

                            Details : DMB-3115 (ustekinumab-biosimilar) is an IL-12/23 inhibitor which is being evaluated in phase 3 clinical trials for the treatment of patients with moderate-to-severe chronic plaque psoriasis.

                            Product Name : DMB-3115

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            May 01, 2024

                            Lead Product(s) : Ustekinumab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Intas Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Accord BioPharma

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Accord BioPharma

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trastuzumab

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Accord BioPharma’s HERCESSI™ (trastuzumab-strf) Approved as Herceptin® Biosimilar in U.S

                            Details : Hercessi (trastuzumab-biosimilar) is a HER2/neu receptor antagonist, which is indicated for HER2 overexpressing breast cancer & metastatic gastric or gastroesophageal junction adenocarcinoma.

                            Product Name : Hercessi

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            April 29, 2024

                            Lead Product(s) : Trastuzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Accord BioPharma

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Accord BioPharma

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Leuprolide Mesylate

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Eversana

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Accord Bio and EVERSANA Announce Partnership to Support the Launch of CAMCEVI

                            Details : CAMCEVI is the first-ever ready-to-inject sterile formulation of leuprolide for subcutaneous injection that comes in a pre-filled syringe with no mixing required. In an open-label, single-arm study of 137 adults who received 42mg of CAMCEVI on Day 0 and ...

                            Product Name : Camcevi

                            Product Type : Hormone

                            Upfront Cash : Undisclosed

                            June 29, 2022

                            Lead Product(s) : Leuprolide Mesylate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Eversana

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth